Clinical trials: Depression NOS
Major Depression
Research Study for Major Depressive Disorder: Investigation of Glutamate Medications
This study is examining the safety and effectiveness of two medications, ketamine and riluzole, in treating patients with treatment resistant major depressive disorder.
- Trial name
- NCT00419003
- Testing
- Lamotrigine, Ketamine, Riluzole
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Baylor College of Medicine
Depressive Episodes, Bipolar I Depression
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder.
A clinical trial to study the efficacy and safety of an investigational drug in people with major depressive episodes associated with with Bipolar I disorder (bipolar I depression) Participants in the study will either receive…
- Trial name
- NCT05169710
- Testing
- SEP-4199 CR 200 mg, SEP-4199 CR 400 mg
- Where
- 89 sites in United States, Bulgaria and 4 more
- Volunteers
- 83 people
- Sponsor
- Sumitomo Pharma America, Inc.
Hypercapnia, Ventilatory Depression
Clinical Study to Investigate the Effect of the Combination of Psychotropic Drugs and an Opioid on Ventilation
Opioids can decrease breathing and co-administration of benzodiazepines with opioids can further decrease breathing. It is unknown whether certain other drugs also decrease breathing when co-administered with opioids.
- Trial name
- NCT04310579
- Testing
- Oxycodone and Midazolam, Oxycodone, Paroxetine, and Quetiapine
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Food and Drug Administration (FDA)
Depression, Anxiety
Evaluation of a Crowd-Powered Web Platform for Depression and Anxiety
100 participants will be enrolled in a two-armed randomized controlled trial of the Accumulated Depression and Anxiety Plans and Treatments (ADAPT) platform which integrates internet Cognitive Behavioral Therapy (iCBT) to…
- Trial name
- NCT04226742
- Testing
- ADAPT Platform (Treatment), ADAPT Comparison (Control)
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- University of California, Irvine
Depression
Sequential Treatment of Pediatric MDD to Increase Remission and Prevent Relapse
This study will compare the effectiveness of fluoxetine alone with the effectiveness of fluoxetine with cognitive behavioral therapy in increasing recovery and preventing relapse in youth with major depressive disorder.
- Trial name
- NCT00612313
- Testing
- Fluoxetine, Relapse prevention cognitive behavioral therapy (CBT)
- Where
- United States
- Volunteers
- 144 people
- Sponsor
- University of Texas Southwestern Medical Center
Depressive Disorder, Treatment-Resistant
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression
The purpose of this study is to evaluate the efficacy and safety of switching elderly participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to either…
- Trial name
- TRANSFORM-3 (NCT02422186)
- Testing
- Esketamine, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant)
- Where
- 69 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Major
Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study
The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.
- Trial name
- NCT01152996
- Testing
- Vortioxetine
- Volunteers
- 1,075 people
- Sponsor
- Takeda
Bipolar I Disorder, Mania
A Cariprazine Study in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current Episode is Manic or Depressive, With or Without Mixed Features
1) To evaluate the efficacy and safety of cariprazine at a target dose of 3.0 mg/day compared with placebo in prevention of relapse in patients with bipolar I disorder whose current episode (i.e.
- Conditions
- Bipolar I Disorder, Mania, Depression
- Trial name
- NCT03573297
- Testing
- Cariprazine
- Where
- 108 sites in United States, Bulgaria and 9 more
- Volunteers
- 901 people
- Sponsor
- AbbVie
Depression, Postpartum
Minimum Intervention to Maintain a Postpartum Depression Prevention Program in Clinics Serving Low-income Women
Postpartum depression (PPD) is common and can have lasting consequences for mother and child. ROSE is an intervention to prevent PPD, delivered during pregnancy in outpatient prenatal settings.
- Trial name
- ROSE (NCT03267563)
- Testing
- EIAU, LICF, HICF
- Where
- United States
- Volunteers
- 160 people
- Sponsor
- Michigan State University
Depression, Postpartum, Depression, Unipolar
Tracking Depression Symptoms With a Health Chatbot
The goal of this research is to bridge a significant "effectiveness" gap in the treatment of depression. The investigators have developed a chatbot which will assist in performing measurement-based care (MBC) via Facebook…
- Trial name
- NCT03990389
- Testing
- Chatbot Intervention
- Where
- 2 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Treatment Resistant Depression
BPL-003 Efficacy and Safety in Treatment Resistant Depression
This is a Phase 2 study randomized, quadruple-masked, multi-center trial with an open-label extension (OLE), designed to investigate the efficacy and safety of BPL-003 in patients with treatment resistant depression (TRD).
- Trial name
- NCT05870540
- Testing
- BPL-003
- Where
- 42 sites in United States, Australia and 4 more
- Volunteers
- 196 people
- Sponsor
- Beckley Psytech Limited
Depression
Fevarin® Effectiveness in Treatment of Depression in Patients With Neurological Disorder
Prospective, multicenter, non-comparative, observational program to describe prevalence of depressive symptoms in a variety of neurological disorders and effects of Fevarin® on the severity of anxiety and depression, sleep state…
- Trial name
- FRIENDS (NCT02043197)
- Where
- 29 sites in Russia
- Volunteers
- 300 people
- Sponsor
- Abbott
Depression
[11C]-(R)-Rolipram to Measure cAMP Signaling Before and After Ketamine
Background: Major depressive disorder (MDD) may have many underlying causes. One theory is that brain cells with low levels of a molecule called cyclic AMP (cAMP) may cause depression.
- Trial name
- NCT05522673
- Testing
- 11(R)-rolipram
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Mental Health (NIMH)
Anxiety, Depression
Effectiveness of CES on Emotional and Cellular Wellbeing
The investigators aim to use a CES (cranial electrotherapy stimulation) intervention to improve emotional well-being by reducing symptoms of anxiety and depression and to assess for changes in markers of cellular health …
- Trial name
- NCT03369418
- Testing
- Alpha-Stim Active, Alpha-Stim Inactive
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Treatment Resistant Depression
Tianeptine for Treatment Resistant Depression
The studies will be conducted in parallel at two sites: the the Mood and Anxiety Disorders Program at the Icahn School of Medicine at Mount Sinai (MSSM), and Stanford Depression Research Clinic at Stanford University School of…
- Trial name
- NCT04249596
- Testing
- Tianeptine Sodium
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Jonathan A. Javitch, MD, PhD
LGBTQ, Sexual Behavior
A Trial of Online LGBTQ-affirmative Cognitive Behavioral Therapy to Reduce Depression and Associated Health Risks Among Young Adults
This study is to test the efficacy of an online CBT intervention (EQuIP) that addresses the pathways through which minority stress compromises LGBTQ young adults' co-occurring mental (e.g., depression) and behavioral (e.g.…
- Trial name
- NCT04408469
- Testing
- Online EQuIP, Self-monitoring control
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Yale University
Depressive Disorder
Memantine Augmentation of Antidepressants
This study is evaluating the efficacy and safety of the drug memantine (trade name NAMENDA) as an augmentation agent for the treatment of depression in people who are not fully responding to antidepressant medications.
- Trial name
- NCT00344682
- Testing
- memantine
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Massachusetts, Worcester
Bipolar Depression
Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally
The study will evaluate the efficacy and safety of ITI-007 in a randomized, double-blind, parallel-group, placebo-controlled, multi-center study in patients diagnosed with Bipolar I or Bipolar II disorder having a major…
- Trial name
- NCT03249376
- Testing
- Lumateperone
- Where
- 47 sites in United States, Bulgaria and 4 more
- Volunteers
- 381 people
- Sponsor
- Intra-Cellular Therapies, Inc.
Alcohol; Use, Problem, Stress
A Behavioral Activation Intervention Administered in a College Freshman Orientation Course
The transition from high school to college is a developmentally sensitive period that is high risk for escalations in alcohol use.
- Conditions
- Alcohol; Use, Problem, Stress, Binge Eating, Depression
- Trial name
- NCT04038190
- Testing
- behavioral activation
- Where
- United States
- Volunteers
- 572 people, healthy volunteers welcome
- Sponsor
- University of Kansas
Depression, Bipolar Depression
Low Field Magnetic Stimulation in Mood Disorders Using the LFMS Device
This study is designed to test whether low-field magnetic stimulation (LFMS) can relieve some of the symptoms of depression in bipolar disorder or major depression.
- Conditions
- Depression, Bipolar Depression, Major Depressive Disorder
- Trial name
- LFMS (NCT00578383)
- Testing
- Low Field Magnetic Stimulation Device
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- Mclean Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.